University Briefs

Taxing Grants . . . And Patience You've got to give Pittsburgh city officials points for creativity. In their zest to find new sources of tax revenue, they recently targeted the research grants of scientists at Carnegie Mellon University and the University of Pittsburgh as long-overlooked cash cows. In an article in the Pittsburgh Press (Feb. 25, 1990), director of finance Ben Hayllar was quoted as saying the city intended to investigate whether research grants from private corporations were su

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Taxing Grants . . . And Patience You've got to give Pittsburgh city officials points for creativity. In their zest to find new sources of tax revenue, they recently targeted the research grants of scientists at Carnegie Mellon University and the University of Pittsburgh as long-overlooked cash cows. In an article in the Pittsburgh Press (Feb. 25, 1990), director of finance Ben Hayllar was quoted as saying the city intended to investigate whether research grants from private corporations were subject to the municipality's business privilege tax. For Pitt, which received $143.2 million in research grants in fiscal 1989, this meant that the $11.6 million it received from corporations was at risk. The total was even higher at CMU, where $18.9 million of its $120.7 million fiscal year 1989 total was from private companies. Luckily for Iron City scientists, the hasty notion was just as quickly abandoned. "The fact is we ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies